Generate Biomedicines (NASDAQ:GENB) Stock Price Down 6% – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB) shares traded down 6% on Tuesday. The company traded as low as $12.95 and last traded at $13.01. 225,037 shares changed hands during trading, a decline of 73% from the average daily volume of 843,769 shares. The stock had previously closed at $13.84.

Wall Street Analysts Forecast Growth

GENB has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Generate Biomedicines in a research report on Monday, October 5th. Weiss Ratings upgraded shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Finally, Wall Street Zen raised Generate Biomedicines from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.40.

Generate Biomedicines Stock Up 2.1%

The company has a 50 day moving average of $15.48 and a two-hundred day moving average of $14.43.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. As a group, analysts predict that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. State Street Corp bought a new stake in Generate Biomedicines during the second quarter worth about $8,883,000. Braidwell LP bought a new position in shares of Generate Biomedicines during the second quarter valued at approximately $55,398,000. Squarepoint Ops LLC bought a new position in shares of Generate Biomedicines during the second quarter valued at approximately $530,000. The Manufacturers Life Insurance Company purchased a new position in shares of Generate Biomedicines during the second quarter valued at approximately $1,431,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Generate Biomedicines during the second quarter valued at approximately $967,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.